Search

Your search keyword '"Asanin, Milika R."' showing total 17 results

Search Constraints

Start Over You searched for: Author "Asanin, Milika R." Remove constraint Author: "Asanin, Milika R."
17 results on '"Asanin, Milika R."'

Search Results

1. Prognostic Implications of the Timing of ST-Elevation Myocardial Infarction Development in Relation to COVID-19 Infection.

2. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

3. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

4. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

7. Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention

8. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

9. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

10. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

11. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

12. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

13. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

14. Impact on long-term mortality of access and non-access site bleeding after primary percutaneous coronary intervention

15. Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention

16. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

17. The long-term risk of stroke in patients with acute myocardial infarction complicated with new-onset atrial fibrillation.

Catalog

Books, media, physical & digital resources